24 Dec 2019
Posted in Influencer
Ten of the most popular cardiovascular tweets in November 2019, revealed by GlobalData
From wearable health devices to cardiovascular risks in women, leading data and analytics company GlobalData lists ten of the most popular tweets in cardiovascular in November 2019, based on data from the company’s Influencer Platform.
- Eric Topol’s tweet about wearable health devices
American cardiologist and digital medicine researcher Eric Topol shared an article detailing the growing significance of wearable health devices such as the Apple Watch series in maintaining heart health.
On 26th November 2019, @EricTopol tweeted: “How to obtain a full 12-lead electrocardiogram via the @Apple watch (which normally gets one lead, lead 1)https://annals.org/aim/article-abstract/2756147/standard-precordial-leads-obtained-apple-watch … by @cobos_cardio @AnnalsofIM w/ demo tracings from patients with a heart attack and an instructive video,” which collected 498 likes and 263 retweets.
- Gregg W Stone’s tweet about improved quality of life and reduced angina for patients with baseline angina
Interventional cardiologist Gregg W Stone tweeted about the ISCHEMIA trial’s results, including improved quality of life and reduced angina in patients with any baseline angina with invasive surgery.
On 17th November 2019, @GreggWStone tweeted: “4/8 #ISCHEMIA: Substantial reduction in angina and improved QOL in pts w/any baseline angina with invasive approach. NNT to make 1 pt angina-free =~3-5! Benefits were sustained through 3+ yrs (unlike COURAGE in non-DES era). Minimal differences in asymptomatic pts.” which saw 165 likes and 84 retweets.
- Eric Topol’s tweet on cancer increasing the risk of deaths from cardiovascular disease
Eric Topol tweeted that cancer patients have between a two and six times higher risk of dying from heart disease and stroke. The physician and scientist shared an article in his tweet detailing that nearly half the deaths in breast, endometrial, prostate and thyroid cancer are caused due to cardiovascular disease (CVD).
On 25th November 2019, @EricTopol tweeted: “Patients w/ #cancer have a 2-6 times higher mortality from cardiovascular disease than the general population https://www.eurekalert.org/pub_releases/2019-11/esoc-cpa112119.php … @escardio @ESC_Journals report by @NicholasZaorsky, Kathleen Sturgeon @PSHResearch and collaborators; editorial by @mayocvonc,” which gained 165 likes and 99 retweets.
- Dr Rohin Francis’ tweet about how incomplete data can be misleading
Cambridge-trained cardiologist Dr Rohin Francis tweeted about misleading data in light of how some recent research concluded that smokers saw better health following a heart attack, when compared to non-smokers, although the former suffered more heart attacks.
On 5th November 2019, @MedCrisis tweeted: “A little tidbit for non-cardiologists who might not’ve heard of the Smoker’s Paradox. WHY INCOMPLETE DATA CAN MISLEAD! Yrs ago it was observed that although smokers had more heart attacks (MIs), they actually did *better* after having had one, compared to a non-smoker. wtf?” which attracted 230 likes and 94 retweets.
- Mamas’ tweet on dapagliflozoc in reducing cardiovascular deaths
Consultant interventional cardiologist Mamas tweeted about the benefits of dapagliflozoc in reducing cardiovascular deaths, hospitalisation and urgent heart failure visits. The influencer shared an infographic from the American Heart Association (AHA) Scientific Sessions 2019 to state that dapagliflozoc helped in reducing heart failures and cardiovascular deaths in standard therapy.
On 16th November 2019, @mmamas1973 tweeted: “Dapa-HF benefit of dapaglifozocin consistent & of similar magnitude in DM and non-DM. decrease cv death, hospitalisation and urgent HF visit in non-dm, same benefit even in norm hba1c. Should cardiologists be responsible for starting SGLT2i? #AHA2019 #aha19 @DrMarthaGulati,” which saw 145 likes and 71 retweets.
- David L Fischman’s tweet on Impella versus IABP in acute myocardial infarction
Cardiologist David L Fischman tweeted that Impella could have worse outcomes in a real-world scenario against the traditional intra-aortic balloon pump (IABP) used in treating acute myocardial infarction. He noted that this could further be complicated by a cardiogenic shock or the sudden inability of the heart to pump blood for the body.
On 17th November 2019, @fischman_david tweeted: “Let the discussion begin. In real world study Impella associated with worse outcomes compared to IABP in AMI-Cardiogenic Shock Patient undergoing #PCI #AHA19,” which attracted 147 likes and 59 retweets.
- Dr Deepak’s tweet about icosapent ethyl’s ability to reduce all-cause mortality in US patients
A professor of medicine at the Harvard Medical School, Dr Deepak L Bhatt, shared an article highlighting that icosapent ethyl reduces the risk of developing cardiovascular diseases, with a 30% reduction in all-cause mortality among US patients.
On 11th November 2019, @DLBHATTMD tweeted: “Cardiovascular risk in the USA: Now we can REDUCE-IT w/ icosapent ethyl, including a statistically significant 30% reduction in all-cause mortality in US patients! REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States | Circulation https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044440#.XclDUWKQUPg.twitter …,” which collected 160 likes and 58 retweets.
- Mamas’ tweet on the best practices to prevent radial occlusion (RAO)
Cardiologist Mamas also shared an article on how to prevent radial occlusion (RAO) after a transradial diagnostic angiography and intervention. One of the biggest complications associated with RAO is that the same radial artery cannot be used for future procedures.
On 19th November 2019, @mmamas1973 tweeted: “1. Our consensus paper re best practices to decrease radial occlusion (RAO) led by Ivo Bernat, adel aminian & Olivier bertrand published with @SVRaoMD @Radial_ICG @samirpancholy @nolanjimradial http://interventions.onlinejacc.org/content/12/22/2235 … RAO most frequent complication of #RadialFirst @rwyeh,” which collected 120 likes and 52 retweets.
- SekKathiresan’s tweet about the effectiveness of low-dose Colchicine in reducing cardiovascular events
Physician-geneticist SekKathiresan shared an article on the safety and efficacy of low-dose colchicine for reducing cardiovascular events. They also shared an article by the New England Journal of Medicine, which stated that a randomised trial was conducted on patients diagnosed with myocardial infarction.
On 16th November 2019, @skathire tweeted: “This is wild! Addition of low-dose colchicine (0.5mg) (an anti-inflammatory drug around for centuries) to standard-of-care significantly reduces CV events Further evidence to support this concept: reduce inflammation to Rx CADhttps://www.nejm.org/doi/full/10.1056/NEJMoa1912388?query=featured_home …,” which collected 113 likes and 42 retweets.
- Dr Purvi’s tweet on long-term cardiovascular risks in women
Dr Purvi Parwani, a cardiologist based in California, tweeted about the cardiovascular risks associated with hypertension in pregnancy. She shared an article posted by the Journal of the American College of Cardiology (JACC), which stated that a history of hypertensive disorder of pregnancy (HDP) should be helpful in detecting cardiovascular risks in women.
On 22nd November 2019, @purviparwani tweeted: “Important paper for #womenCVD in @JACCJournals on Hypertensive Disease of Pregnancy(HDP)-40-69 years with ≥1birth n= 220,024 – HDP ->CAD, CHF, AS, MR- The development of chronic HTN doesn’t explain all the associated risk http://bit.ly/2QDgos7,” which saw 79 likes and 38 retweets.